TIAMATE Drug Patent Profile

When do Tiamate patents expire, and what generic alternatives are available?

Tiamate is a drug marketed by Merck and is included in one NDA.

The generic ingredient in TIAMATE is diltiazem malate. There are twenty-six drug master file entries for this compound. Additional details are available on the diltiazem malate profile page.

Summary for TIAMATE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	58
Patent Applications:	48
DailyMed Link:	TIAMATE at DailyMed

US Patents and Regulatory Information for TIAMATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-001	Oct 4, 1996		DISCN	No	No
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-002	Oct 4, 1996		DISCN	No	No
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-003	Oct 4, 1996		DISCN	No	No

Expired US Patents for TIAMATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-001	Oct 4, 1996
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-003	Oct 4, 1996
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-003	Oct 4, 1996
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-001	Oct 4, 1996
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-002	Oct 4, 1996
Merck	TIAMATE	diltiazem malate	TABLET, EXTENDED RELEASE;ORAL	020506-002	Oct 4, 1996

International Patents for TIAMATE

See the table below for patents covering TIAMATE around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1320885	POMPE OSMOTIQUE A POROSITE CONTROLEE (CONTROLLED POROSITY OSMOTIC PUMP)
Cyprus	1652	CONTROLLED POROSITY OSMOTIC PUMP
Ireland	851524
Latvia	5786	Osmotiskais suknis ar regulejamu porainibu
New Zealand	226179	CONTROLLED POROSITY OSMOTIC PUMP FOR SUSTAINED RELEASE OF PHARMACEUTICAL AGENTS
Singapore	16393

Market Dynamics and Financial Trajectory for Protein Expression and Related Technologies

Introduction

The field of protein expression, closely related to technologies like molecular farming and biotechnological advancements, is experiencing significant growth. This article will delve into the market dynamics, financial projections, and key drivers influencing this sector.

Global Protein Expression Market

The global protein expression market is on a steep growth trajectory. As of 2023, the market was valued at USD 4.24 billion and is projected to reach USD 12.27 billion by 2033, growing at a CAGR of 10.45% from 2024 to 2033[1].

Key Market Segments

By Product

• The reagents segment held a 41% revenue share in 2023, indicating a strong demand for the materials necessary for protein expression processes.
• The services segment is growing at a CAGR of 12.5% from 2024 to 2033, highlighting the increasing need for specialized services in this field[1].

By Application

• The therapeutic segment captured a 51% revenue share in 2023, reflecting the critical role of protein expression in developing and monitoring therapeutic products[1].

By End-use

• Pharmaceutical and biotechnological businesses held a 46% revenue share in 2023, underscoring the sector's reliance on protein expression technologies[1].

Molecular Farming: A Key Driver

Molecular farming, which involves using plants or animals to produce proteins and enzymes, is a significant driver in this market. This method is cost-effective and scalable, making it attractive for pharmaceutical applications.

• The molecular farming market is expected to grow from $454.1 million in 2023 to $916.3 million by 2028, at a CAGR of 15.1% during the forecast period. This growth is driven by increasing demand for proteins from the pharmaceutical industry and increased funding in molecular farming research[4].

Innovations and Breakthroughs

Recent innovations are further propelling the market forward. For instance, Tiamat Sciences Corporation's breakthrough in mRNA enzyme production using plant systems is a notable example. This involves introducing T7 polymerase into plants to produce enzymes crucial for mRNA synthesis, which could lead to more efficient vaccine development[1].

Regional Stance

• The United States is a key player in this market, with companies like Tiamat Sciences Corporation and Aviva Systems Biology making significant contributions to protein expression and molecular farming technologies[1].

Financial Performance and Projections

The financial performance of companies involved in protein expression and related technologies is robust. Here are some key financial highlights:

• Revenue Growth: The protein expression market is expected to more than double from 2024 to 2033, with a CAGR of 10.45%. This growth is driven by increasing applications in gene therapy, bioanalysis, and therapeutic product development[1].

• Segmental Growth: The services segment is expected to grow at a CAGR of 12.5%, indicating a strong demand for specialized services in protein expression[1].

Industry Experts and Quotes

Industry experts emphasize the importance of these technologies in addressing health challenges. For example, the success in producing mRNA enzymes in plant systems is seen as a significant step forward in vaccine development:

"This success paves the way for progress in the quest to develop more effective, efficient and potentially effective vaccines."[1]

Illustrative Statistics

• Market Size: The global protein expression market is projected to reach USD 12.27 billion by 2033 from USD 4.68 billion in 2024[1].
• CAGR: The market is growing at a CAGR of 10.45% from 2024 to 2033[1].
• Segment Revenue: The therapeutic segment captured 51% of the revenue share in 2023[1].

Challenges and Opportunities

While the market is growing rapidly, there are challenges to be addressed, such as the need for advanced bioanalytical techniques to monitor therapeutic effects and safety.

"Bioanalysis is necessary to develop and monitor therapeutic effect and safety. Characterization of DNA and RNA can be done by qPCR, specific protein analysis..."[1]

Key Takeaways

• The global protein expression market is expected to grow significantly, driven by applications in gene therapy and bioanalysis.
• Molecular farming is a key driver, offering cost-effective and scalable methods for protein production.
• Innovations in mRNA enzyme production and other biotechnological advancements are propelling the market forward.
• The services segment is growing rapidly, indicating a strong demand for specialized services.

FAQs

Q: What is the projected market size of the global protein expression market by 2033? A: The global protein expression market is projected to reach USD 12.27 billion by 2033[1].

Q: What is the CAGR of the protein expression market from 2024 to 2033? A: The market is growing at a CAGR of 10.45% from 2024 to 2033[1].

Q: Which segment holds the largest revenue share in the protein expression market? A: The therapeutic segment captured a 51% revenue share in 2023[1].

Q: What is molecular farming, and how does it contribute to the protein expression market? A: Molecular farming involves using plants or animals to produce proteins and enzymes. It is a cost-effective and scalable method that is increasingly used in the pharmaceutical industry[4].

Q: What recent innovation has Tiamat Sciences Corporation achieved in protein expression? A: Tiamat Sciences Corporation has successfully introduced T7 polymerase into the plant system to produce enzymes used in mRNA production, paving the way for more efficient vaccine development[1].

Cited Sources

1. Biospace: "Protein Expression Market Size to Worth USD 12.27 Billion by 2033"
2. UNODC: "Illicit financial flows related to cross-border drug trafficking are comparable to the value of exports of licit markets"
3. Smith+Nephew: "Smith+Nephew Fourth Quarter and Full Year 2023 Results"
4. BCC Research: "Molecular Farming: The Emergence of Global Markets"